Lincoln Nadauld, M.D., Ph.D., is co-founder, President and CEO of Culmination Bio.

Culmination Bio is a technology company spun out of Intermountain Health with a mission to discover better health. Dr. Nadauld and team have built a novel multi-modal health technology platform and insights engine for medical research, health-related data, and healthcare services. Culmination’s intelligence platform generates real-world evidence tied to the performance of diagnostics, therapeutics, and genomic biomarkers.

Dr. Nadauld most recently served as Vice President and Chief of Precision Health at Intermountain Health. He founded the Intermountain Precision Genomics program. He was the founding principal investigator of the HerediGene®: Population Study which is focused on discovering new connections between genetics and human disease across populations greater than 100,000 individuals.

Dr. Nadauld completed combined MD/PhD training at the University of Utah and clinical training in Medical Oncology at Stanford University School of Medicine. His work has been published extensively in peer-reviewed scientific journals.

Dr. Nadauld is married with five children and enjoys attending their many activities and events, water sports, fishing, and other athletic pursuits.